SCHEMBL5546083

SCHEMBL5546083

[O]c1cccc(-n2ccnc2)c1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.69
CYP3A4 P08684 2/20 0.60
CYP2A6 P11509 1/20 0.55
CYP11B1 P15538 3/20 0.54
CYP11B2 P19099 3/20 0.54
CYP19A1 P11511 2/20 0.54
PDE3B Q13370 1/20 0.49
PDE3A Q14432 1/20 0.49
NCOA3 Q9Y6Q9 1/20 0.49
MEN1 O00255 1/20 0.49
ALOX15 P16050 1/20 0.49
TSHR P16473 1/20 0.49
KMT2A Q03164 1/20 0.49
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
ENPP2 Q13822 1/20 0.47
MKNK1 Q9BUB5 1/20 0.47
MKNK2 Q9HBH9 1/20 0.47
NOTUM Q6P988 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14489499 0.86 IDO1 (0.75) IDO1CYP3A4CYP2A6CYP11B1CYP11B2
SCHEMBL710352 0.81 IDO1 (1.00) IDO1CYP3A4CYP2A6CYP11B1CYP11B2
SCHEMBL16716592 0.79 IDO1 (0.65) IDO1CYP3A4CYP2A6CYP11B1CYP11B2
SCHEMBL3071130 0.78 IDO1 (0.64) IDO1CYP3A4CYP2A6CYP11B1CYP11B2
SCHEMBL22114976 0.78 IDO1 (0.64) IDO1CYP3A4CYP2A6CYP11B1CYP11B2
SCHEMBL25138280 0.78 IDO1 (0.64) IDO1CYP3A4CYP2A6CYP11B1CYP11B2
SCHEMBL10346856 0.78 IDO1 (0.64) IDO1CYP3A4CYP2A6CYP11B1CYP11B2
SCHEMBL21020697 0.78 IDO1 (0.64) IDO1CYP3A4CYP2A6CYP11B1CYP11B2
SCHEMBL3152446 0.78 IDO1 (0.64) IDO1CYP3A4CYP2A6CYP11B1CYP11B2
SCHEMBL870900 0.78 IDO1 (0.64) IDO1CYP3A4CYP2A6CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 IDO1 3181/4885CYP3A4 1683/4885CYP2A6 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.